Physician profile
David Speiser
NPI 1932195419
$3,440.95
in general payments reported to CMS, 2019-2025
13 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $208 · 2021: $405 · 2022: $287 · 2023: $763 · 2024: $777 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $890.86 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $531.06 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $514.60 | 2019-2021 | |
| Alcon Vision LLC | $446.82 | 2023-2025 | Simbrinza, Rhopressa, Rocklatan |
| Abbvie INC. | $253.41 | 2023-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $228.42 | 2021-2025 | Cequa |
| Oyster Point Pharma, INC. | $213.64 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $188.31 | 2024-2025 | Xdemvy |
| Allergan, INC. | $47.48 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $43.37 | 2021-2023 | Acuvue |
| Biotissue Holdings INC. | $39.81 | 2024 | |
| Coopervision INC. | $27.07 | 2022 | |
| Sight Sciences, INC. | $16.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Speiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.